Safety and potential efficacy of tacrolimus for treatment of lupus nephritis with persistent proteinuria

Ayumi Uchino, Hiroshi Tsukamoto, Hitoshi Nakashima, Seiji Yoshizawa, Isao Furugo, Hiroki Mitoma, Kensuke Oryoji, Terufumi Shimoda, Hiroaki Niiro, Yoshifumi Tada, Takahisa Yano, Toshiharu Nonaka, Ryozo Oishi, Koichi Akashi, Takahiko Horiuchi

研究成果: ジャーナルへの寄稿記事

27 引用 (Scopus)

抄録

Objectives: To evaluate the safety and potential efficacy of tacrolimus for the treatment of patients with lupus nephritis and persistent proteinuria. Methods: A total of 23 Japanese patients with lupus nephritis (21 females / 2 males) were enrolled in this study. Patients were administered tacrolimus at a dose of 2-3 mg once daily after the evening meal for 6 months. The dose of tacrolimus was unchanged throughout the study period. Concomitant prednisolone therapy was unchanged or gradually tapered, while other immunosuppressants were stopped at the start of tacrolimus treatment. Results: Tacrolimus was well tolerated, and none of the patients developed adverse drug reactions that required discontinuation of the study. Daily urinary protein loss, the U-prot/U-creat ratio, and serum albumin were significantly improved after 4 months, 3 months, and 1 month of treatment with tacrolimus (p<0.05), respectively, and the improvement persisted until 6 months. The serum complement hemolytic activity (CH50), complement C3 level, and CRP level were also significantly improved after treatment with tacrolimus (p<0.05). Improvement of the U-prot/U-creat ratio was most prominent for patients who were in WHO class IV. Conclusion: Tacrolimus is safe and effective as maintenance therapy for patients with lupus nephritis, at least for 6 months. A larger randomised, controlled trial over a longer period is needed to confirm these results.

元の言語英語
ページ(範囲)6-12
ページ数7
ジャーナルClinical and experimental rheumatology
28
発行部数1
出版物ステータス出版済み - 3 23 2010

Fingerprint

Lupus Nephritis
Tacrolimus
Proteinuria
Safety
Therapeutics
Complement C3
Immunosuppressive Agents
Prednisolone
Drug-Related Side Effects and Adverse Reactions
Serum Albumin
Meals
Complement System Proteins
Randomized Controlled Trials
Serum

All Science Journal Classification (ASJC) codes

  • Rheumatology
  • Immunology and Allergy
  • Immunology

これを引用

Safety and potential efficacy of tacrolimus for treatment of lupus nephritis with persistent proteinuria. / Uchino, Ayumi; Tsukamoto, Hiroshi; Nakashima, Hitoshi; Yoshizawa, Seiji; Furugo, Isao; Mitoma, Hiroki; Oryoji, Kensuke; Shimoda, Terufumi; Niiro, Hiroaki; Tada, Yoshifumi; Yano, Takahisa; Nonaka, Toshiharu; Oishi, Ryozo; Akashi, Koichi; Horiuchi, Takahiko.

:: Clinical and experimental rheumatology, 巻 28, 番号 1, 23.03.2010, p. 6-12.

研究成果: ジャーナルへの寄稿記事

Uchino, A, Tsukamoto, H, Nakashima, H, Yoshizawa, S, Furugo, I, Mitoma, H, Oryoji, K, Shimoda, T, Niiro, H, Tada, Y, Yano, T, Nonaka, T, Oishi, R, Akashi, K & Horiuchi, T 2010, 'Safety and potential efficacy of tacrolimus for treatment of lupus nephritis with persistent proteinuria', Clinical and experimental rheumatology, 巻. 28, 番号 1, pp. 6-12.
Uchino, Ayumi ; Tsukamoto, Hiroshi ; Nakashima, Hitoshi ; Yoshizawa, Seiji ; Furugo, Isao ; Mitoma, Hiroki ; Oryoji, Kensuke ; Shimoda, Terufumi ; Niiro, Hiroaki ; Tada, Yoshifumi ; Yano, Takahisa ; Nonaka, Toshiharu ; Oishi, Ryozo ; Akashi, Koichi ; Horiuchi, Takahiko. / Safety and potential efficacy of tacrolimus for treatment of lupus nephritis with persistent proteinuria. :: Clinical and experimental rheumatology. 2010 ; 巻 28, 番号 1. pp. 6-12.
@article{dd67012c766c458db51d8fab40de6b96,
title = "Safety and potential efficacy of tacrolimus for treatment of lupus nephritis with persistent proteinuria",
abstract = "Objectives: To evaluate the safety and potential efficacy of tacrolimus for the treatment of patients with lupus nephritis and persistent proteinuria. Methods: A total of 23 Japanese patients with lupus nephritis (21 females / 2 males) were enrolled in this study. Patients were administered tacrolimus at a dose of 2-3 mg once daily after the evening meal for 6 months. The dose of tacrolimus was unchanged throughout the study period. Concomitant prednisolone therapy was unchanged or gradually tapered, while other immunosuppressants were stopped at the start of tacrolimus treatment. Results: Tacrolimus was well tolerated, and none of the patients developed adverse drug reactions that required discontinuation of the study. Daily urinary protein loss, the U-prot/U-creat ratio, and serum albumin were significantly improved after 4 months, 3 months, and 1 month of treatment with tacrolimus (p<0.05), respectively, and the improvement persisted until 6 months. The serum complement hemolytic activity (CH50), complement C3 level, and CRP level were also significantly improved after treatment with tacrolimus (p<0.05). Improvement of the U-prot/U-creat ratio was most prominent for patients who were in WHO class IV. Conclusion: Tacrolimus is safe and effective as maintenance therapy for patients with lupus nephritis, at least for 6 months. A larger randomised, controlled trial over a longer period is needed to confirm these results.",
author = "Ayumi Uchino and Hiroshi Tsukamoto and Hitoshi Nakashima and Seiji Yoshizawa and Isao Furugo and Hiroki Mitoma and Kensuke Oryoji and Terufumi Shimoda and Hiroaki Niiro and Yoshifumi Tada and Takahisa Yano and Toshiharu Nonaka and Ryozo Oishi and Koichi Akashi and Takahiko Horiuchi",
year = "2010",
month = "3",
day = "23",
language = "English",
volume = "28",
pages = "6--12",
journal = "Clinical and Experimental Rheumatology",
issn = "0392-856X",
publisher = "Clinical and Experimental Rheumatology S.A.S.",
number = "1",

}

TY - JOUR

T1 - Safety and potential efficacy of tacrolimus for treatment of lupus nephritis with persistent proteinuria

AU - Uchino, Ayumi

AU - Tsukamoto, Hiroshi

AU - Nakashima, Hitoshi

AU - Yoshizawa, Seiji

AU - Furugo, Isao

AU - Mitoma, Hiroki

AU - Oryoji, Kensuke

AU - Shimoda, Terufumi

AU - Niiro, Hiroaki

AU - Tada, Yoshifumi

AU - Yano, Takahisa

AU - Nonaka, Toshiharu

AU - Oishi, Ryozo

AU - Akashi, Koichi

AU - Horiuchi, Takahiko

PY - 2010/3/23

Y1 - 2010/3/23

N2 - Objectives: To evaluate the safety and potential efficacy of tacrolimus for the treatment of patients with lupus nephritis and persistent proteinuria. Methods: A total of 23 Japanese patients with lupus nephritis (21 females / 2 males) were enrolled in this study. Patients were administered tacrolimus at a dose of 2-3 mg once daily after the evening meal for 6 months. The dose of tacrolimus was unchanged throughout the study period. Concomitant prednisolone therapy was unchanged or gradually tapered, while other immunosuppressants were stopped at the start of tacrolimus treatment. Results: Tacrolimus was well tolerated, and none of the patients developed adverse drug reactions that required discontinuation of the study. Daily urinary protein loss, the U-prot/U-creat ratio, and serum albumin were significantly improved after 4 months, 3 months, and 1 month of treatment with tacrolimus (p<0.05), respectively, and the improvement persisted until 6 months. The serum complement hemolytic activity (CH50), complement C3 level, and CRP level were also significantly improved after treatment with tacrolimus (p<0.05). Improvement of the U-prot/U-creat ratio was most prominent for patients who were in WHO class IV. Conclusion: Tacrolimus is safe and effective as maintenance therapy for patients with lupus nephritis, at least for 6 months. A larger randomised, controlled trial over a longer period is needed to confirm these results.

AB - Objectives: To evaluate the safety and potential efficacy of tacrolimus for the treatment of patients with lupus nephritis and persistent proteinuria. Methods: A total of 23 Japanese patients with lupus nephritis (21 females / 2 males) were enrolled in this study. Patients were administered tacrolimus at a dose of 2-3 mg once daily after the evening meal for 6 months. The dose of tacrolimus was unchanged throughout the study period. Concomitant prednisolone therapy was unchanged or gradually tapered, while other immunosuppressants were stopped at the start of tacrolimus treatment. Results: Tacrolimus was well tolerated, and none of the patients developed adverse drug reactions that required discontinuation of the study. Daily urinary protein loss, the U-prot/U-creat ratio, and serum albumin were significantly improved after 4 months, 3 months, and 1 month of treatment with tacrolimus (p<0.05), respectively, and the improvement persisted until 6 months. The serum complement hemolytic activity (CH50), complement C3 level, and CRP level were also significantly improved after treatment with tacrolimus (p<0.05). Improvement of the U-prot/U-creat ratio was most prominent for patients who were in WHO class IV. Conclusion: Tacrolimus is safe and effective as maintenance therapy for patients with lupus nephritis, at least for 6 months. A larger randomised, controlled trial over a longer period is needed to confirm these results.

UR - http://www.scopus.com/inward/record.url?scp=77949531673&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77949531673&partnerID=8YFLogxK

M3 - Article

C2 - 20346231

AN - SCOPUS:77949531673

VL - 28

SP - 6

EP - 12

JO - Clinical and Experimental Rheumatology

JF - Clinical and Experimental Rheumatology

SN - 0392-856X

IS - 1

ER -